Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles

Open Access

Original Research

Biomed Res Ther. 2015; 2(12): 409-417

Autologous Bone Marrow Stem Cells combined with Allograft Cancellous Bone in Treatment of Nonunion

Le Thua Trung Hau, Duc Phu Bui, Nguyen Duy Thang, Pham Dang Nhat, Le Quy Bao, Nguyen Phan Huy, Tran Ngoc Vu, Le Phuoc Quang, Boeckx willy Denis, Mey Albert De.

Autologous cancellous bone graft is currently used as a gold standard method for treatment of bone nonunion. However, there is a limit to the amount of autologous cancellous bone that can be harvested and the donor site morbidity presents a major disadvantage to autologous bone grafting. Embedding viable cells within biological scaffolds appears to be extremely promising. The purpose of this study was to assess the outcome of autologous bone marrow stem cells combined with a cancellous bone allograft as compared to an autologous bone graft in the treatment of bone nonunion. Bone marrow aspiration concentrate (BMAC) was previously produced from bone marrow aspirate via a density gradient centrifugation. Autologous cancellous bone was harvested in 9 patients and applied to the nonunion site. In 18 patients of the clinical trial group after the debridement, the bone gaps were filled with a composite of BMAC and allograft cancellous bone chips (BMAC-ACB). Bone consolidation was obtained in 88.9 %, and the mean interval between the cell transplantation and union was 4.6 ± 1.5 months in the autograft group. Bone union rate was 94.4 % in group of composite BMAC-ACB implantation. The time to union in BMAC-ACB grafting group was 3.3 ± 0.90 months, and led to faster healing when compared to the autograft. A mean concentration of autologous progenitor cells was found to be 2.43 ± 1.03 (x106) CD34+ cells/ml, and a mean viability of CD34+ cells was 97.97 ± 1.47 (%). This study shows that the implantation of BMAC has presented the efficacy for treatment of nonunion and may contribute an available alternative to autologous cancellous bone graft. But large clinical application of BM-MSCs requires a more appropriate and profound scientific investigations.

Key words: Nonunion, mesenchymal stem cells, bone marrow mesenchymal stem cells, bone marrow aspiration concentrate, autologous cancellous bone graft

Similar Articles

The promise of neuroprotection by dietary restriction in glaucoma.
Russo R, Nucci C, Adornetto A
Neural regeneration research. 2022; 17(1): 45-47

Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease.
Goulding SR, Anantha J, Collins LM, Sullivan AM, O'Keeffe GW
Neural regeneration research. 2022; 17(1): 38-44

Presenilin mutations and their impact on neuronal differentiation in Alzheimer's disease.
Hernandez-Sapiens MA, Reza-Zaldívar EE, Márquez-Aguirre AL, Gómez-Pinedo U, Matias-Guiu J, Cevallos RR, Mateos-Díaz JC, Sánchez-González VJ, Canales-Aguirre AA
Neural regeneration research. 2022; 17(1): 31-37

Delving into the recent advancements of spinal cord injury treatment: a review of recent progress.
Flack JA, Sharma KD, Xie JY
Neural regeneration research. 2022; 17(2): 283-291

Transcranial magnetic stimulation in animal models of neurodegeneration.
Uzair M, Abualait T, Arshad M, Yoo WK, Mir A, Bunyan RF, Bashir S
Neural regeneration research. 2022; 17(2): 251-265

Full-text options

Add your Article(s) to Indexes
• citeindex.org

Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.